Abstract
Propranolol has been employed for a long time in clinical practice as non selective β-adrenoreceptor antagonist. Only the S(−) optical isomer has β-blocking activity, whereas R(+) form is totally ineffective. Early clinical observations (1978–1979) showed that treatment with propranolol improved blood platelet function in patients with cardiovascular diseases. In vitro studies indicated that this compound inhibited human PRP aggregation following exposure to ADP, collagen, epinephrine and Ca2+ ionophore A23187, and diminished aggregation of washed human platelets induced by a low concentration (0.025 U/ml) of thrombin (1). Both S(−) and R (+) isomers as well as (±) racemic form were active. Further studies evaluated the inhibitory effect of propranolol on phosphatidic acid (PA) phosphohydrolase, which converts PA to diacylglycerol in various type of cells (2). It was found that inhibition of PA phosphohydrolase by propranolol led to potentiation of 02 production in neutrophils stimulated with putative receptor agonist fMLP, suggesting a role for PA as a second messenger and for PA phosphohydrolase as a key regulatory enzyme in the interaction between PLC and PLD in the signal transduction (3,4). Sozzani et al., showed recently (5), that both S(−) and R(+) form inhibited protein kinase C (PKC) from human neutrophils and reduced [3H]PDBu binding by neutrophils in the concentration range of 100–200 μM.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Weksler, B.B., Gillick, M. and Pink, J. Blood 49:185–196, 1977.
Koul, O. and Hauser, G. Arch. Biochem. Biophys. 253:453–461, 1987.
Agwu, D.E., NcPhail, L.C., Sozzani, S., Bass, D.A. and McCall, C.E. J. Clin. Invest. 88:531–539, 1991.
Gay, J.C. and Murray, J.J. Biochim. Biophys. Acta 1095:236–242, 1991.
Sozzani, S., Agwu, D.E., McCall, C.E., O’Flaherty, J.T., Schmitt, J.D., Kent, J.D. and McPhail, L.C. J. Biol. Chem. 267:20481–20488, 1992.
Rittenhouse, S.E. and Sasson, J.P. J. Biol. Chem. 260:8657–8660, 1985.
Geanacopoulos, M., Turner, J., Bowling, K.E., Vandenberg, S.R. and Gear, A.R.L. Thrombosis Res. 69:113–124, 1993.
Tate, B.F. and Rittenhouse, S.E. Biochim. Biophys. Acta. 1178:281–285, 1993.
Rubin, R. Biochem. Biophys. Res. Commun. 156:1090–1096, 1988.
Ekholm, J., Tatsumi, Y., Nouchi, T. and Hanahan, D.J. Anal. Biochem, 204:79–84, 1992.
Thompson, N.T., Bonser, R.W. and Garland, CG. Trends in Pharmacol. Sci. 12:404–408, 1991.
Conricode, K.M., Brewer, K.A. and Exton, J.H. J. Biol. Chem. 267:7199–7202, 1992.
Baidassare, J.J., Henderson, P.A., Burns, D., Loomis, C. and Fisher, G. J. Biol. Chem. 267:15585–15590, 1992.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Svetlov, S.I., Hanahan, D.J. (1997). Dual Effect of Propranolol on the Human Platelet Activation by Thrombin: Potentiation of Free Intracellular Ca2+ Mobilization and Inhibition of Phospholipase D Activity. In: Honn, K.V., Nigam, S., Marnett, L.J. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2. Advances in Experimental Medicine and Biology, vol 400. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5325-0_29
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5325-0_29
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7430-5
Online ISBN: 978-1-4615-5325-0
eBook Packages: Springer Book Archive